Sepsis-Induced Coagulopathy: An Update on Pathophysiology, Biomarkers, and Current Guidelines
Andreas G. Tsantes,Stavroula Parastatidou,Emmanuel A. Tsantes,Elli Bonova,Konstantina A. Tsante,Petros G. Mantzios,Aristeidis G. Vaiopoulos,Stavros Tsalas,Aikaterini Konstantinidi,Dimitra Houhoula,Nicoletta Iacovidou,Daniele Piovani,Georgios K. Nikolopoulos,Rozeta Sokou
DOI: https://doi.org/10.3390/life13020350
2023-01-29
Life
Abstract:Significant cross talk occurs between inflammation and coagulation. Thus, coagulopathy is common in sepsis, potentially aggravating the prognosis. Initially, septic patients tend to exhibit a prothrombotic state through extrinsic pathway activation, cytokine-induced coagulation amplification, anticoagulant pathways suppression, and fibrinolysis impairment. In late sepsis stages, with the establishment of disseminated intravascular coagulation (DIC), hypocoagulability ensues. Traditional laboratory findings of sepsis, including thrombocytopenia, increased prothrombin time (PT) and fibrin degradation products (FDPs), and decreased fibrinogen, only present late in the course of sepsis. A recently introduced definition of sepsis-induced coagulopathy (SIC) aims to identify patients at an earlier stage when changes to coagulation status are still reversible. Nonconventional assays, such as the measurement of anticoagulant proteins and nuclear material levels, and viscoelastic studies, have shown promising sensitivity and specificity in detecting patients at risk for DIC, allowing for timely therapeutic interventions. This review outlines current insights into the pathophysiological mechanisms and diagnostic options of SIC.
biology